Aller au contenu principal
Accès ouvert déclaré 2025 article

Evolution of the inappropriate use of broad-spectrum antibiotics for Pseudomonas aeruginosa infections following the 2022 CA-SFM guidelines

0Citations signalées — pas une note de qualité
5Institutions déclarées
1Pays d’affiliation déclarés

Résumé fourni par la source

INTRODUCTION: The European Committee on Antimicrobial Susceptibility Testing (EUCAST) changed the definition of the 'intermediate' (I) category in 2019, now defined as 'susceptible, increased exposure'. We previously reported an increase in prescriptions for antibiotics still reported as 'S', compared with those now reported as 'I'. This study aimed to evaluate the influence of a more explicit abbreviation (SFP or 'Susceptible increased exposure') than 'I' on the use of overly broad-spectrum antibiotics for the treatment of infections caused by wild-type (WT) Pseudomonas aeruginosa. METHODS: A retrospective observational multicenter study was conducted across five hospitals. Two study periods were defined, before and after the implementation of the new abbreviation (from September 2020 to February 2022, and from March 2022 to August 2023). All patients with an infection caused by WT P.aeruginosa treated with β-lactams were included. The main endpoint was the proportion of patients treated with an overly broad-spectrum antibiotic treatment by meropenem or ceftolozane/tazobactam. RESULTS: A total of 279 patients were included. No difference between groups was found, in terms of infection, microbiology, or demographic characteristics. Eight overly broad-spectrum antibiotic treatments by meropenem or ceftolozane/tazobactam were observed in Period 1 (5.6 %), versus one in Period 2 (0.7 %; p = 0.026). No overly broad-spectrum treatment was observed when the antimicrobial stewardship team had given advice. CONCLUSIONS: The French recommendations derived from the EUCAST guidelines, with a new abbreviation, have contributed to a reduction in the prescription of broad-spectrum antibiotics and have helped mitigate clinicians' misunderstanding of the previous guidelines.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Evolution of the inappropriate use of broad-spectrum antibiotics for Pseudomonas aeruginosa infections following the 2022 CA-SFM guidelines
Date Crossref
01/12/2025
Éditeur
Elsevier BV
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Antibiotic Use and ResistanceAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and Efficacy

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.